Evidence map›Paper›PMID 36507224›Full record

ArticleiScience2022

The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant.

Izumi Kimura, Daichi Yamasoba, Hesham Nasser, Jiri Zahradnik, Yusuke Kosugi, Jiaqi Wu, Kayoko Nagata, Keiya Uriu, Yuri L Tanaka, Jumpei Ito and 17 more

Abstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Izumi KimuraDivision of Systems Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.
Daichi YamasobaDivision of Systems Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.
Hesham NasserDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.
Jiri ZahradnikDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.
Yusuke KosugiDivision of Systems Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.
Jiaqi WuDepartment of Molecular Life Science, Tokai University School of Medicine, Isehara 2591193, Japan.
Kayoko NagataDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
Keiya UriuDivision of Systems Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.
Yuri L TanakaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan.
Jumpei ItoDivision of Systems Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.
Ryo ShimizuDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.
Toong Seng TanDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.
Erika P ButlertanakaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan.
Hiroyuki AsakuraTokyo Metropolitan Institute of Public Health, Tokyo 1690073, Japan.
Kenji SadamasuTokyo Metropolitan Institute of Public Health, Tokyo 1690073, Japan.
Kazuhisa YoshimuraTokyo Metropolitan Institute of Public Health, Tokyo 1690073, Japan.
Takamasa UenoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
Gideon SchreiberDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.
Genotype to Phenotype Japan (G2P-Japan) Consortium
Mako ToyodaDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.
Kotaro ShirakawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
Takashi IrieInstitute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 7398511, Japan.
Akatsuki SaitoDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan.
So NakagawaDepartment of Molecular Life Science, Tokai University School of Medicine, Isehara 2591193, Japan.
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.
Kei SatoDivision of Systems Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have revealed the unique virological characteristics of Omicron, particularly those of its spike protein, such as less cleavage efficacy in cells, reduced ACE2 binding affinity, and poor fusogenicity. However, it remains unclear which mutation(s) determine these three virological characteristics of Omicron spike. Here, we show that these characteristics of the Omicron spike protein are determined by its receptor-binding domain. Of interest, molecular phylogenetic analysis revealed that acquisition of the spike S375F mutation was closely associated with the explosive spread of Omicron in the human population. We further elucidated that the F375 residue forms an interprotomer pi-pi interaction with the H505 residue of another protomer in the spike trimer, conferring the attenuated cleavage efficiency and fusogenicity of Omicron spike. Our data shed light on the evolutionary events underlying the emergence of Omicron at the molecular level.

Indexed as

Molecular biologyVirology

Identifiers

PMID36507224
PMCPMC9719929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.